 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
25 News |  |
- pasotuxizumab (BAY2010112) / Amgen, Bayer
Inhibition of the de-ubiquitinse USP30 in human fibroblasts from IPF patients suppresses the fibrotic response (PS-6; Poster board no. 13) - May 31, 2024 - Abstract #ERS2024ERS_3796;
MTX112 at 10 and 30nM significantly (p<0.05) improved mitochondrial function by 50% in IPF fibroblasts. Targeting USP30 may therefore be a novel therapeutic strategy for the treatment of pulmonary fibrosis by improving pulmonary fibroblast mitochondrial function and slowing tissue fibrosis, potentially halting disease progression.
- | pasotuxizumab (BAY2010112) / Amgen, Bayer
Journal: Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy. (Pubmed Central) - Nov 13, 2023
P1
Through a series of stepwise functional assays, our investigation revealed that alongside a more historically immunogenic route of administration, non-tolerant T cell epitopes within the AMG 212 amino acid sequence were likely driving the high-titer, sustained ADA response observed in the SC arm. These mechanistic insights into the AMG 212 ADA response underscore the importance of performing preclinical immunogenicity risk evaluation as well as advocate for continuous iteration to better our biologics.
- | pasotuxizumab (BAY2010112) / Amgen, Bayer
Journal: Pasotuxizumab, a BiTE immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. (Pubmed Central) - Feb 9, 2022
P1
Data support pasotuxizumab safety in advanced castration-resistant prostate cancer and represent evidence of BiTE monotherapy efficacy in solid tumors. Clinical trial registration: NCT01723475 (ClinicalTrials.gov).
- || pasotuxizumab (BAY2010112) / Amgen, Bayer
Interesting - didn't Amgen already have a PSMAxCD3 bispecific (AMG 212) or has that one gone by the wayside already? (Twitter) - Jul 27, 2021
- |||| pasotuxizumab (BAY2010112) / Amgen, Bayer
Clinical, P1 data: Pasotuxizumab - no remissions per Recist in first-in-human mCRPC, but recruitment had been halted when $AMGN bought $MITI #GU20 (Twitter) - Feb 14, 2020
- pasotuxizumab (BAY2010112) / Amgen, Bayer
Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). (Poster Board F4) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_587;
P1
There were two long term responders in the dose escalation. This is the first clinical study showing that a BiTE immune therapy can be efficacious in solid tumors.
- pasotuxizumab (BAY2010112) / Amgen, Bayer
Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). (Poster Board F4) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_284;
P1
There were two long term responders in the dose escalation. This is the first clinical study showing that a BiTE immune therapy can be efficacious in solid tumors.
- ||| pasotuxizumab (BAY2010112) / Amgen, Bayer
Will keep my eyes 👀 on AMG 212 (pasotuximab): The monoclonal antibody a promising target prostate-specific membrane antigen (PSMA) to treat #mCRPC @TSchlomm @FabioSchutz78 @cnsternberg @DrChoueiri @Uromigos @GeSRU_de @uroupdate @martin_schostak @declangmurphy (Twitter) - Oct 28, 2019
- AMG 160 / Amgen
A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2942;
P1
A recent trial with pasotuxizumab (AMG 212), a canonical BiTE ® molecule targeting PSMA, demonstrated preliminary antitumor activity in mCRPC...Key inclusion criteria: age ≥18 years; histologically or cytologically confirmed mCRPC refractory to enzalutamide, abiraterone, and/or apalutamide; have failed 1–2 taxane-based regimens or are medically unsuitable for or refuse a taxane regimen; bilateral orchiectomy or on continuous androgen-deprivation therapy; evidence of progressive disease...Legal entity responsible for the study: Amgen Inc. Funding: Amgen Inc.
- ||||| pasotuxizumab (BAY2010112) / Amgen, Bayer
Interesting bispecific antibody targeting PSMA and T cells with nice responses observed in mCRPC. #ASCO19 #pasotuxizumab (Twitter) - Jun 1, 2019
- || pasotuxizumab (BAY2010112) / Amgen, Bayer
Trial completion: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Nov 1, 2018
P1, N=47, Completed, Sponsor: Bayer
Funding: Amgen Inc. Active, not recruiting --> Completed
- || pasotuxizumab (BAY2010112) / Amgen, Bayer
Enrollment closed, Trial completion date: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Jul 23, 2018
P1, N=47, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Completed --> Active, not recruiting | Trial completion date: Jul 2018 --> Oct 2018
- || pasotuxizumab (BAY2010112) / Amgen, Bayer
Trial completion, Trial completion date, Trial primary completion date: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Jul 11, 2018
P1, N=47, Completed, Sponsor: Bayer
Completed --> Active, not recruiting | Trial completion date: Jul 2018 --> Oct 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018
- pasotuxizumab (BAY2010112) / Amgen, Bayer
Trial primary completion date: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Dec 22, 2017
P1, N=45, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- pasotuxizumab (BAY2010112) / Amgen, Bayer
Trial primary completion date: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Nov 6, 2017
P1, N=45, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Aug 2017 --> Dec 2017
- pasotuxizumab (BAY2010112) / Amgen, Bayer
Trial primary completion date: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - May 18, 2017
P1, N=45, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: May 2017 --> Aug 2017
- pasotuxizumab (BAY2010112) / Amgen, Bayer
Enrollment closed, Enrollment change: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Jan 24, 2017
P1, N=45, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: May 2017 --> Aug 2017 Recruiting --> Active, not recruiting | N=70 --> 45
- || pasotuxizumab (BAY2010112) / Amgen, Bayer
Trial primary completion date: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Sep 16, 2016
P1, N=70, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=70 --> 45 Trial primary completion date: Dec 2016 --> May 2017
- || pasotuxizumab (BAY2010112) / Amgen, Bayer
Trial primary completion date: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Sep 24, 2015
P1, N=70, Recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2016 --> May 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- || pasotuxizumab (BAY2010112) / Amgen, Bayer
Trial primary completion date: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - May 1, 2014
P1, N=70, Recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: May 2015 --> Dec 2015
- | pasotuxizumab (BAY2010112) / Amgen, Bayer
Trial completion date: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - May 1, 2014
P1, N=70, Recruiting, Sponsor: Bayer
Trial primary completion date: May 2015 --> Dec 2015 Trial completion date: May 2015 --> Dec 2015
- ||| pasotuxizumab (BAY2010112) / Amgen, Bayer
New P1 trial: First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer (clinicaltrials.gov) - Nov 6, 2012
P1, N=70, Recruiting, Sponsor: Bayer